Exploring sleep‐related outcomes in patients with mild to moderate Alzheimer’s disease initiating acetylcholinesterase inhibitor therapy: The Morpheus survey
Year of Publication 2013
Abstract
Presents a study which aims to explore sleep related outcomes in patients with mild moderate Alzheimer’s disease (AD) initiating acetylcholinesterase inhibitor therapy. This study is a prospective, observational, longitudinal, multicentre survey evaluating sleep quality in AD patients initiating acetylcholinesterase inhibitor (AChEI) treatment. Data for this study were collected at AChEI initiation and after 3 to 6 months follow up and a total of baseline cohort included 950 patients. Results reported that 23% patients of the 746 had impaired sleep quality and at the baseline, 42% of patients exhibited at least one symptom described by the Sleep Disorders Inventory (SDI). This study identified factors associated with impaired quality of sleep in patients with mild to moderate AD initiating AChEI therapy. In some individuals, improvements in sleep related outcomes may be apparent after starting AChEI treatment, and benefits associated with improving sleep may therefore accrue. (PsycINFO Database Record (c) 2013 APA, all rights reserved)